Jefferies Initiates Coverage On Vaxart with Buy Rating, Announces Price Target of $13
Jefferies analyst Kelechi Chikere initiates coverage on Vaxart (NASDAQ:VXRT) with a Buy rating and announces Price Target of $13.
Stifel Initiates Coverage On PLBY Group with Buy Rating, Announces Price Target of $52
Stifel analyst Jim Duffy initiates coverage on PLBY Group (NASDAQ:PLBY) with a Buy rating and announces Price Target of $52.
Oppenheimer Initiates Coverage On Lightning eMotors with Outperform Rating, Announces Price Target of $15
Oppenheimer analyst Colin Rusch initiates coverage on Lightning eMotors (NYSE:ZEV) with a Outperform rating and announces Price Target of $15.
Goldman Sachs Initiates Coverage On TCR2 Therapeutics with Buy Rating, Announces Price Target of $30
Goldman Sachs analyst Salveen Richter initiates coverage on TCR2 Therapeutics (NASDAQ:TCRR) with a Buy rating and announces Price Target of $30.
Stifel Initiates Coverage On Denbury with Buy Rating, Announces Price Target of $93
Stifel analyst Michael Scialla initiates coverage on Denbury (NYSE:DEN) with a Buy rating and announces Price Target of $93.
UBS Initiates Coverage On Colgate-Palmolive with Buy Rating, Announces Price Target of $95
UBS analyst Peter Grom initiates coverage on Colgate-Palmolive (NYSE:CL) with a Buy rating and announces Price Target of $95.
DA Davidson Initiates Coverage On Affirm Holdings with Buy Rating, Announces Price Target of $80
DA Davidson initiates coverage on Affirm Holdings (NASDAQ:AFRM) with a Buy rating and announces Price Target of $80.
Oppenheimer Initiates Coverage On Oaktree Specialty Lending with Outperform Rating, Announces Price Target of $7.5
Oppenheimer analyst Mitchel Penn initiates coverage on Oaktree Specialty Lending (NASDAQ:OCSL) with a Outperform rating and announces Price Target of $7.5.
UBS Initiates Coverage On Clorox with Sell Rating, Announces Price Target of $166
UBS analyst Peter Grom initiates coverage on Clorox (NYSE:CLX) with a Sell rating and announces Price Target of $166.
UBS Initiates Coverage On Scotts Miracle Gro with Buy Rating, Announces Price Target of $225
UBS analyst Peter Grom initiates coverage on Scotts Miracle Gro (NYSE:SMG) with a Buy rating and announces Price Target of $225.